Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 8/31/21 → 4/24/23 |
Funding
- IQVIA RDS Incorporated: $21,578.00
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Munker, Reinhold (PI)